Business
Aeterna Zentaris Announces Poster Presentation on Final Phase 2 Results for AEZS-108 in Endometrial Cancer at Upcoming European Society of Gynaecological Oncology Meeting
Jul. 18, 2011 (Canada NewsWire Group) -- QUÉBEC CITY, July 18, 2011 /CNW Telbec/ - Aeter...
About this update from Cosciens Biopharma Inc.
[{"type":"text","content":"\n\n\n Jul. 18, 2011 (Canada NewsWire Group) -- \n\n#ReleaseContent TABLE\n{\n BORDER-COLLAPSE: collapse\n}\nTR.cnwUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTR.cnwDoubleUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTR.cnwBoldUnderlinedCell TD\n{\n BORDER-BOTTOM: #000000 3px solid\n}\nTD.cnwUnderlinedCell\n{\n BORDER-BOTTOM: #000000 1px solid\n}\nTD.cnwDoubleUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px double\n}\nTD.cnwBoldUnderlinedCell\n{\n BORDER-BOTTOM: #000000 3px solid\n}\n#ReleaseContent TABLE.cnwBorderedTable TD\n{\n BORDER-RIGHT: black 1px solid;\n PADDING-RIGHT: 2px;\n BORDER-TOP: black 1px solid;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n BORDER-LEFT: black 1px solid;\n PADDING-TOP: 2px;\n BORDER-BOTTOM: black 1px solid;\n BORDER-COLLAPSE: collapse\n}\n#ReleaseContent TABLE TD\n{\n PADDING-RIGHT: 2px;\n PADDING-LEFT: 2px;\n PADDING-BOTTOM: 2px;\n PADDING-TOP: 2px\n}\n\n\nQUÉBEC CITY, July 18, 2011 /CNW Telbec/ - Aeterna Zentaris Inc. (NASDAQ:\n AEZS) (TSX: AEZ) (the "Company")  today announced that final Phase 2\n results in endometrial cancer on its anticancer compound, AEZS-108,\n will be presented during a poster session at the upcoming 17th International Meeting of the European Society of Gynaecological\n Oncology ("ESGO"), to be held September 11-14, 2011, at the Milan\n Convention Center in Milan, Italy. The trial was conducted by the\n German AGO Study Group and study centers in Bulgaria. AEZS-108, a\n targeted cytotoxic peptide conjugate, is currently in Phase 1/2\n programs in prostate and bladder cancer, and has successfully completed\n Phase 2 trials in endometrial and ovarian cancer.\n\n\n\n\n\n\n\nAbstract #247: \n\n\n"AGO-GYN 5 - (Phase II) study with AEZS-108, a targeted cytotoxic LHRH\n analog in patients with LHRH receptor positive endometrial cancer", Wimberger P., Gorchev G., Hanker L., Stähle A., Hristamian A.,\n Beckmann M.W., Dall P., Gründker C., Hilpert F., Sehouli J., Harter P.,\n Taskova V., Emons G., AGO Study Group, Germany\n\n\n\n\n \n\n\n \n\n\n\n\nPresenter: \n\n\nPauline Wimberger, MD, Gynaecology and Obstetrics, University of\n Duisburg-Essen, Essen, Germany\n\n\n\n\nPoster Session: \n\n\nPoster Shift III\n\n\n\n\nDate and time: \n\n\nSeptember 14, 2011 / 7:00-8:00 ...